Salix Pharmaceuticals has bagged the ex-Asia rights to Mitsubishi Tanabe’s late-phase autoimmune drug, amiselimod. The Bausch Health subsidiary plans to trial the S1P receptor functional antagonist in ulcerative colitis.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,